The global veterinary biologics market is forecasted to grow from USD 14 billion in 2025 to USD 25.7 billion by 2035, advancing at a compound annual growth rate (CAGR) of 6.3%, according to recent industry estimates. This growth is driven by the rising prevalence of infectious diseases among livestock and companion animals, increased investment in animal health infrastructure, and technological innovation in vaccine development.
As global demand for animal-derived food products continues to rise, maintaining herd immunity through vaccination has become essential for ensuring productivity and mitigating economic losses. Veterinary biologics—including vaccines, monoclonal antibodies, and immunomodulators—play a critical role in disease prevention and improving immunity against viral and bacterial infections across multiple animal categories.
Rising Livestock Immunization and Food Security Focus Drive Market Growth
The expansion of intensive animal farming, particularly in poultry, swine, and cattle sectors, is increasing the need for advanced biologics to control disease outbreaks. Governments and international organizations such as the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) are spearheading immunization initiatives to safeguard animal and public health.
The livestock segment accounts for nearly USD 9.5 billion of the global market in 2025 and is projected to grow at a 6.5% CAGR through 2035. Growth is particularly strong in Asia, Latin America, and Africa, where livestock production is expanding to meet protein demand.
Meanwhile, the companion animal sector is witnessing accelerated biologics adoption amid rising pet ownership and the growing “humanization of pets.” Preventive healthcare and wellness trends are propelling the uptake of vaccines and immunostimulants in the canine and feline categories.
Get exclusive access to detailed market statistics and trends — request your free sample report today!
Vaccines Remain the Cornerstone of Market Expansion
Vaccines continue to dominate the market, contributing USD 8.38 billion in 2025 and projected to reach USD 15.07 billion by 2035, reflecting a 6.8% CAGR. Their broad applications—ranging from attenuated live, conjugate, and inactivated vaccines to recombinant and DNA-based formulations—ensure their relevance across livestock and companion animals alike.
The evolution of vaccine technologies, including vector-based, recombinant DNA, and mRNA platforms, is enabling faster, safer, and more targeted immunization. Global manufacturers are increasingly developing combination vaccines that reduce the number of injections required, improving compliance for both veterinarians and farmers.
Technological Innovation and Global R&D Accelerate Progress
Biotechnology breakthroughs are reshaping the veterinary biologics landscape. Companies such as Zoetis Inc., Merck & Co., Boehringer Ingelheim, Elanco Animal Health, and Ceva Santé Animale are investing heavily in next-generation vaccines and monoclonal antibody therapies.
These innovations are being fast-tracked through collaborations between biotech firms, academic institutions, and government health agencies—a response to the growing importance of animal health in the One Health framework, which links human, animal, and environmental wellbeing.
Recent announcements highlight this momentum:
- Ceva Santé Animale unveiled new vaccine manufacturing facilities in Europe in late 2024 to expand poultry and swine vaccine production.
- Elanco Animal Health secured FDA approval for Credelio Quattro, a multi-parasite treatment for dogs.
- Advanced Instruments announced a merger with Nova Biomedical in March 2025 to strengthen innovation in biological tools and diagnostics.
Veterinary Clinics Lead Distribution Networks
Veterinary clinics remain the most significant distribution channel, holding a 6.1% CAGR through 2035. Clinics are the primary points of contact for preventive care and vaccine administration, particularly in urban and peri-urban regions. Their trust-based relationships with pet owners and farmers make them key drivers of biologics adoption.
Veterinary hospitals, research institutions, and retail pharmacies also contribute to market expansion, though their share remains secondary compared to clinics, which offer consistent, direct engagement in vaccination programs.
Regional Insights: North America and Europe Lead, Asia-Pacific Rising Fast
The United States continues to dominate global revenues, advancing at a 6.0% CAGR, driven by a well-established veterinary infrastructure and strong USDA and FDA oversight ensuring product quality and safety.
In Europe, Germany (6.5%) and France (6.2%) lead growth, supported by sustainable livestock policies and rising demand for recombinant and monoclonal antibody-based biologics. The United Kingdom maintains steady expansion, benefiting from digital veterinary services and post-Brexit regulatory harmonization.
Across Asia-Pacific, Japan (5.8%) and India are witnessing robust demand due to growing pet ownership, biosecurity investments, and heightened awareness of zoonotic diseases.
Key Growth Drivers and Market Challenges
Market Drivers:
- Increasing zoonotic disease prevalence and government-backed immunization programs
- Growing pet ownership and preventive animal healthcare awareness
- Advances in recombinant, DNA, and vector-based vaccine technology
- Rising global protein demand and livestock productivity requirements
Market Challenges:
- High R&D and regulatory compliance costs
- Cold-chain logistics constraints in emerging markets
- Diverse regional regulatory frameworks affecting product launch timelines
Competitive Outlook
The market remains moderately consolidated, with top players—Zoetis, Merck, Boehringer Ingelheim, Elanco, and Ceva—commanding the majority share. Regional producers such as Hester Biosciences, HIPRA, and Virbac are strengthening their presence through localized vaccine production and strategic alliances.
Emerging trends point toward AI-assisted vaccine development, digital cold chain monitoring, and customized autogenous biologics designed to address region-specific outbreaks—ushering in a new era of precision veterinary immunization.
Purchase Full Report for Detailed Insights
For access to full forecasts, regional breakouts, company share analysis, and emerging trend assessments, you can purchase the complete report here: Buy Full Report – Veterinary Biologics Market
Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us – [email protected]
About Future Market Insights (FMI)
Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.
